Disease with no cure

With no cure for RA, early diagnosis and effective treatment are the best ways to help reduce damaging effects and improve patients’ quality of life.

239,700+*

RA patients followed prospectively with deep clinical, lab, and other linked data

*Counts are based on Q2 2023 registry release

1.9 Million+*

RA patients in the OM1 Real-World Data Cloud that can be used for modeling, analysis, and other research purposes

Learn about the OM1 RA Registry:

• Poster (ACR Convergence 2021): A Cross-Sectional Study of Rheumatoid Arthritis (RA) Diagnoses in Patients with Systemic Lupus Erythematosus (SLE)
• Publication (RMD Open, Nov 2021): Validation of a Machine Learning Approach to Estimate Clinical Disease Activity Index Scores for Rheumatoid Arthritis
• Poster (EULAR 2021): Patient Characteristics and Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: The OM1 RA Registry
• Article (Osteoporosis International, July 2020): Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis
• Poster (ICPE 2019): Improvements in Disease Activity Scores Associated with bDMARD use by Rheumatoid Arthritis Patients in a Large US-Based Real World Cohort
• Poster (AMCP 2019): Age and Gender Differences in Comorbidities among Patients with Rheumatoid Arthritis in a Large US-Based Real World Cohort

• Poster (ISPOR 2019): Depression and Patient Outcomes Among Rheumatoid Arthritis Patients in a Large US-Based Real World Cohort
• Poster (ACR/ARHP 2017): Initiation of Biologic Disease Modifying Antirheumatic Drug Therapy and Associated Changes in Disease Activity Measures in Routine Clinical Practice: Findings from a Large Contemporaneous Real World Cohort
• Abstract (ACR/ARHP 2017): Comparison of Improvements in Disease Activity between Classes of Biologic Disease Modifying Anti-Rheumatic Drugs in Routine Clinical Practice: Findings from a Large Contemporaneous Real World Cohort
• Poster (ISPOR 2017): Initiation of Biologic Disease Modifying Antirheumatic Drug Therapy and Associated Changes in Disease Activity Measures in Routine Clinical Practice: Findings from a Next Generation Registry
• Poster (ISPOR 2017): Patient Reported Outcomes and Changes in DMARD Therapy for Rheumatoid Arthritis in Routine Clinical Practice